IP Library › Granted Patent US 12,303,570
Granted Patent B2
US 12,303,570 · App. 17/492,260 · Granted May 20, 2025

Compositions and methods for assessing eye vasculature

Inventors: Richard B. Dorshow (Ballwin, MO); Thomas E. Rogers (Ballwin, MO)
Assignee: MEDIBEACON INC.
A61K49/0021A61B5/0071C07D241/20C07K5/06139A61B1/042A61B5/0082A61B5/0261
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,303,570
App. No.
17/492,260
Granted
May 20, 2025
Kind
B2
Abstract

Compositions and methods for assessing blood vessels and organs of the body are disclosed herein, specifically methods for assessing the vasculature of the eye.

Claims (67)

1. A method for assessing the eye vasculature in a subject in need thereof, comprising the steps of:

a. administering an effective amount of a compound of structural Formula I

or a salt thereof; wherein

X 1 and X 2 are independently chosen from —CO(AA), —CN, —CO 2 R 1 , —CONR 2 R 3 , —COR 4 , —NO 2 , —SOR 35 , —SO 2 R 6 , —SO 2 OR 7 and —PO 3 R 8 R 9 ; wherein at least one of X 1 and X 2 is —CO(AA);

Y 1 and Y 2 are independently chosen from —OR 10 , —SR 11 , —NR 12 R 13 , —N(R 14 )COR 15 , —CONH(PS); —P(R 16 ) 2 , —P(OR 17 ) 2 and

each Z 1 is independently chosen from a bond, —CR 18 R 19 —, —O—, —NR 20 —, —NCOR 21 —, —S—, —SO—, and —SO 2 —;

each R 1 to R 21 are independently chosen from hydrogen, C 1 -C 10 alkyl, C 1 -C 10 alkyl substituted with hydroxyl and carboxylic acid, C 3 -C 6 polyhydroxylated alkyl, C 5 -C 10 aryl, C 5 -C 10 heteroaryl, C 3 -C 5 heterocycloalkyl, C 3 -C 5 heterocycloalkyl substituted with C(O), —(CH 2 ) a CO 2 H, —(CH 2 ) a CO 2 H substituted with C 5 -C 10 heteroaryl, —(CH 2 ) a CONR 30 R 31 , —(CH 2 ) a NHSO 3 − , —(CH 2 ) a NHSO 3 H, —(CH 2 ) a OH, —(CH 2 ) a OPO 3 − , —(CH 2 ) a OPO 3 H 2 , —(CH 2 ) a OPO 3 H − , (CH 2 ) a OR 22 , —(CH 2 ) a OSO 3 − , —(CH 2 ) a OSO 3 H, —(CH 2 ) a PO 3 − , —(CH 2 ) a PO 3 H 2 , —(CH 2 ) a PO 3 H − , —(CH 2 ) a SO 3 − , —(CH 2 ) a SO 3 H, —(CH 2 ) d CO(CH 2 CH 2 O) c R 23 , —(CH 2 ) d (CH 2 CH 2 O) c R 24 , —(CHCO 2 H) a CO 2 H, —CH 2 (CHNH 2 ) a CH 2 NR 25 R 26 , —CH 2 (CHOH) a CO 2 H, —CH 2 (CHOH) a R 27 , —CH[(CH 2 ) b NH 2 ] a CH 2 OH, —CH[(CH 2 ) b NH 2 ] a CO 2 H, and —(CH 2 ) a NR 28 R 29 ;

each R 22 to R 31 are independently chosen from hydrogen, C 1 -C 10 alkyl, and C 1 -C 5 -dicarboxylic acid;

R 35 is chosen from C 1 -C 10 alkyl, C 1 -C 10 alkyl substituted with hydroxyl and carboxylic acid, C 3 -C 6 polyhydroxylated alkyl, C 5 -C 10 aryl, C 5 -C 10 heteroaryl, C 3 -C 5 heterocycloalkyl, C 3 -C 5 heterocycloalkyl substituted with C(O), —(CH 2 ) a CO 2 H, —(CH 2 ) a CO 2 H substituted with C 5 -C 10 heteroaryl, —(CH 2 ) a CONR 30 R 31 , —(CH 2 ) a NHSO 3 − , —(CH 2 ) a NHSO 3 H, —(CH 2 ) a OH, —(CH 2 ) a OPO 3 − , —(CH 2 ) a OPO 3 H 2 , —(CH 2 ) a OPO 3 H − , —(CH 2 ) a OR 21 , —(CH 2 ) a OSO 3 − , —(CH 2 ) a OSO 3 H, —(CH) a PO 3 − , —(CH 2 ) a PO 3 H 2 , —(CH 2 ) a PO 3 H − , —(CH 2 ) a SO 3 − , —(CH 2 ) a SO 3 H, —(CH 2 ) d CO(CH 2 CH 2 O) c R 23 , —(CH 2 ) d (CH 2 CH 2 O) c R 24 , —(CHCO 2 H) n CO 2 H, —CH 2 (CHNH 2 ) a CH 2 NR 25 R 26 , —CH 2 (CHOH) a CO 2 H, —CH 2 (CHOH) a R 27 , —CH[(CH 2 ) b NH 2 ] a CH 2 OH, —CH[(CH 2 ) b NH 2 ] a CO 2 H, and —(CH 2 ) a NR 28 R 29 ;

(AA) is a polypeptide chain comprising one or more natural or unnatural amino acids linked together by peptide bonds;

(PS) is a sulfated or non-sulfated polysaccharide chain comprising one or more monosaccharide units connected by glycosidic linkages; and

each ‘a’, ‘b’, and ‘d’ are independently chosen from 0 to 10, ‘c’ is chosen from 1 to 100 and each of ‘m’ and ‘n’ independently is an integer from 1 to 3; and

b. irradiating the subject's eye vasculature with non-ionizing radiation, wherein the radiation causes the compound to fluoresce;

c. detecting the fluorescence of the compound in the subject's eye vasculature; and

d. assessing the eye vasculature within the subject based on the detected fluorescence.

2. The method of claim 1 , wherein the compound is administered intravenously, subcutaneously or intraperitoneally.

3. The method of claim 1 , wherein the non-ionizing radiation has a wavelength of at least 350 nm.

4. The method of claim 1 , wherein the detected fluorescence of the compound in the subject's eye vasculature is measured over time.

5. The method of claim 1 , wherein the method further comprises assessing the subject's pulmonary and cardiac vasculature.

6. The method of claim 1 , wherein the method further comprises diagnosing the subject's renal function.

7. The method of claim 6 , wherein diagnosing the subject's renal function comprises:

exposing the compound to visible or near infrared light;

detecting spectral energy emanating from the compound after administering the compound to the subject; and

determining clearance of the compound from the body of the patient;

wherein the compound absorbs and emanates spectral energy in the visible and/or near infrared spectrum.

8. The method of claim 7 , further comprising comparing the subject's clearance of the compound to that of a normal clearance profile.

9. The method of claim 1 , wherein assessing the subject's eye vasculature comprises identifying ocular abnormalities.

10. The method of claim 9 , wherein the ocular abnormalities are selected from the group consisting of blood vessel architecture, ischemic spots, choroidal infarcts, Elschnig's spots, exudates, hemorrhages, and combinations thereof.

11. The method of claim 9 , wherein the ocular abnormalities are selected from the group consisting of vessel crossovers, vessel tortuosity, evidence of exudates, and combinations thereof.

12. The method of claim 1 , wherein assessing the subject's eye vasculature comprises comparing the detected fluorescence in the subject's eye to that of a normal eye under similar conditions.

13. The method of claim 1 wherein X 1 and X 2 are each —CO(AA) and Y 1 and Y 2 are each —NR 12 R 13 wherein one of R 12 and R 13 is hydrogen and the other of R 12 and R 13 is selected from the group consisting of hydrogen and C 1 -C 10 alkyl.

14. The method of claim 13 wherein each of R 12 and R 13 is hydrogen.

15. The method of claim 1 wherein the compound of structural formula I is

16. A method of assessing the location of a disease or an injury in a subject's eye vasculature, comprising the steps of:

a. administering an effective amount of a compound of structural Formula I

or a salt thereof; wherein

X 1 and X 2 are independently chosen from —CO(AA), —CN, —CO 2 R 1 , —CONR 2 R 3 , —COR 4 , —NO 2 , —SOR 35 , —SO 2 R 6 , —SO 2 OR 7 and —PO 3 R 8 R 9 ; wherein at least one of X 1 and X 2 is —CO(AA);

Y 1 and Y 2 are independently chosen from —OR 10 , —SR 11 , —NR 12R 13 , —N(R 14 )COR 15 , —CONH(PS); —P(R 16 ) 2 , —P(OR 17 ) 2 and

each Z 1 is independently chosen from a bond, —CR 18 R 19 —, —O—, —NR 20 —, —NCOR 21 —, —S, —SO—, and —SO 2 —;

each R 1 to R 21 are independently chosen from hydrogen, C 1 -C 10 alkyl, C 1 -C 10 alkyl substituted with hydroxyl and carboxylic acid, C 3 -C 6 polyhydroxylated alkyl, C 5 -C 10 aryl, C 5 -C 10 heteroaryl, C 3 -C 5 heterocycloalkyl, C 3 -C 5 heterocycloalkyl substituted with C(O), —(CH 2 ) a CO 2 H, —(CH 2 ) a CO 2 H substituted with C 5 -C 10 heteroaryl, —(CH 2 ) a CONR 30 R 31 , —(CH 2 ) a NHSO 3 − , —(CH 2 ) a NHSO 3 H, —(CH 2 ) a OH, —(CH 2 ) a OPO 3 − , —(CH 2 ) a OPO 3 H 2 , —(CH 2 ) a OPO 3 H − , (CH 2 ) a OR 22 , —(CH 2 ) a OSO 3 − , —(CH 2 ) a OSO 3 H, —(CH 2 ) a PO 3 − , —(CH 2 ) a PO 3 H 2 , —(CH) a PO 3 H − , —(CH 2 ) a SO 3 − , —(CH 2 ) a SO 3 H, —(CH 2 ) d CO(CH 2 CH 2 O) c R 23 , —(CH 2 ) d (CH 2 CH 2 O) c R 24 , —(CHCO 2 H) a CO 2 H, —CH 2 (CHNH 2 ) a CH 2 NR 25 R 26 , —CH 2 (CHOH) a CO 2 H, —CH 2 (CHOH) a R 27 , —CH[(CH 2 ) b NH 2 ] a CH 2 OH, —CH[(CH 2 ) b NH 2 ] a CO 2 H, and —(CH) a NR 28 R 29 ;

each R 22 to R 31 are independently chosen from hydrogen, C 1 -C 10 alkyl, and C 1 -C 5 -dicarboxylic acid;

R 35 is chosen from C 1 -C 10 alkyl, C 1 -C 10 alkyl substituted with hydroxyl and carboxylic acid, C 3 -C 6 polyhydroxylated alkyl, C 5 -C 10 aryl, C 5 -C 10 heteroaryl, C 3 -C 5 heterocycloalkyl, C 3 -C 5 heterocycloalkyl substituted with C(O), —(CH 2 ) a CO 2 H, —(CH 2 ) a CO 2 H substituted with C 5 -C 10 heteroaryl, —(CH 2 ) a CONR 30 R 31 , —(CH 2 ) a NHSO 3 − , —(CH 2 ) a NHSO 3 H, —(CH 2 ) a OH, —(CH 2 ) a OPO 3 − , —(CH 2 ) a OPO 3 H 2 , —(CH 2 ) a OPO 3 H − , —(CH 2 ) a OR 22 , —(CH 2 ) a OSO 3 − , —(CH 2 ) a OSO 3 H, —(CH 2 ) a PO 3 − , —(CH 2 ) a PO 3 H 2 , —(CH 2 ) a PO 3 H − , —(CH 2 ) a SO 3 − , —(CH 2 ) a SO 3 H, —(CH 2 ) d CO(CH 2 CH 2 O) c R 23 , —(CH 2 ) d (CH 2 CH 2 O) c R 24 , —(CHCO 2 H) a CO 2 H, —CH 2 (CHNH 2 ) a CH 2 NR 25 R 26 , —CH 2 (CHOH) a CO 2 H, —CH 2 (CHOH) a R 27 , —CH [(CH 2 ) b NH 2 ] a CH 2 OH, —CH[(CH 2 ) b NH 2 ] a CO 2 H, and —(CH 2 ) a NR 28 R 29 ;

(AA) is a polypeptide chain comprising one or more natural or unnatural amino acids linked together by peptide bonds;

(PS) is a sulfated or non-sulfated polysaccharide chain comprising one or more monosaccharide units connected by glycosidic linkages; and

each ‘a’, ‘b’, and ‘d’ are independently chosen from 0 to 10, ‘c’ is chosen from 1 to 100 and each of ‘m’ and ‘n’ independently is an integer from 1 to 3; and;

b. irradiating the subject's eye vasculature with non-ionizing radiation, wherein the radiation causes the compound to fluoresce;

c. detecting the fluorescence of the compound in the subject's eye vasculature; and

d. assessing the location of disease or injury in the subject's eye vasculature, based on the detected fluorescence.

17. The method of claim 16 , wherein the compound is administered intravenously, subcutaneously or intraperitoneally.

18. The method of claim 16 , wherein the non-ionizing radiation has a wavelength of at least 350 nm.

19. The method of claim 16 , wherein the detected fluorescence of the compound in the subject's eye vasculature is measured over time.

20. The method of claim 16 , wherein the method further comprises assessing the subject's pulmonary and cardiac vasculature.

21. The method of claim 16 , wherein assessing the location of a disease or an injury in a the subject's eye vasculature comprises identifying ocular abnormalities.

22. The method of claim 21 , wherein the ocular abnormalities are selected from the group consisting of blood vessel architecture, ischemic spots, choroidal infarcts, Elschnig's spots, exudates, hemorrhages, and combinations thereof.

23. The method of claim 21 , wherein the ocular abnormalities are selected from the group consisting of vessel crossovers, vessel tortuosity, evidence of exudates, and combinations thereof.

24. The method of claim 21 , wherein assessing the location of a disease or an injury in the subject's eye vasculature comprises comparing the detected fluorescence in the subject's eye to that of a normal eye under similar conditions.

25. The method of claim 16 , wherein said amino acids are chosen from α-amino acids, β-amino acids, and γ-amino acids.

26. The method of claim 16 wherein X 1 and X 2 are each —CO(AA) and Y 1 and Y 2 are each —NR 12 R 13 wherein one of R 12 and R 13 is hydrogen and the other of R 12 and R 13 is selected from the group consisting of hydrogen and C 1 -C 10 alkyl.

27. The method of claim 26 wherein each of R 12 and R 13 is hydrogen.

28. The method of claim 16 wherein the compound of structural formula I is

29. The method of claim 16 , wherein the method further comprises diagnosing the subject's renal function.

30. The method of claim 29 , wherein diagnosing the subject's renal function comprises:

exposing the compound to visible or near infrared light;

detecting spectral energy emanating from the compound after administering the compound to the subject; and

determining clearance of the compound from the body of the patient;

wherein the compound absorbs and emanates spectral energy in the visible and/or near infrared spectrum.

31. The method of claim 30 , further comprising comparing the subject's clearance of the compound to that of a normal clearance profile.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2025
From: DORSHOW, RICHARD B.; ROGERS, THOMAS E.
To: MEDIBEACON INC.
Reel/Frame 070345/0678 →
Continuity (5)
Continuation 16694982 · Nov 25, 2019
Division 15572706
Provisional Application 62160338 · May 12, 2015
Related Publication 20220016269A1 · Jan 20, 2022
Related Publication 20230132384A9 · Apr 27, 2023
References Cited (81)
US 3814747A · Donald · 1974 [cited by applicant]
US 3814757A · Donald · 1974 [cited by applicant]
US 3948895A · Donald · 1976 [cited by applicant]
US 6440950B1 · Zeimer · 2002 [cited by examiner]
US 8115000B2 · Rajagopalan · 2012 [cited by examiner]
US 8722685B2 · Rajagopalan et al. · 2014 [cited by applicant]
US 9216963B2 · Neumann et al. · 2015 [cited by applicant]
US 9283288B2 · Dorshow et al. · 2016 [cited by applicant]
US 9480687B2 · Rajagopalan et al. · 2016 [cited by applicant]
US 10898591B2 · Dorshow · 2021 [cited by examiner]
US 11160880B2 · Dorshow · 2021 [cited by examiner]
US 20030236452A1 · Melker et al. · 2003 [cited by applicant]
US 20060095102A1 · Perex · 2006 [cited by applicant]
US 20080281173A1 · Esenaliev et al. · 2008 [cited by applicant]
US 20100021382A1 · Dorshow · 2010 [cited by examiner]
US 20110250139A1 · Poreddy et al. · 2011 [cited by applicant]
US 20110250140A1 · Poreddy · 2011 [cited by examiner]
US 20130116512A1 · Imran · 2013 [cited by applicant]
US 20150112192A1 · Docherty et al. · 2015 [cited by applicant]
US 20150306486A1 · Logan et al. · 2015 [cited by applicant]
WO 2007149479A1 · 2007 [cited by applicant]
WO 2010078025A1 · 2010 [cited by applicant]
WO 2010078028A1 · 2010 [cited by applicant]
WO 2014149069A1 · 2014 [cited by applicant]
Acheson et al., “Painful crises in sickle cell disease after fluorescein sodium angiography”, Lancet, 1985, vol. 1, No. 8439, p. 1222. [cited by applicant]
Alario et al., Anterior segment fluorescein angiography of the normal canine eye using a DSLR camera adapter:, Vet Ophthalmol, 2013; vol. 16, pp. 10-19. [cited by applicant]
Ascaso et al., “Fatal acute myocardial infarction after intravenous fluorescein angiography”, Retina, 1993, vol. 13, pp. 238-239. [cited by applicant]
Balbino et al., “Anaphylaxis with convulsions following intravenous fluorescein sodium angiography at an outpatient clinic”, 2012, vol. 10, No. 3, pp. 374-376. [cited by applicant]
Bearelley et al., “Anaphylaxis following intravenous fluorescein sodium angiography in a vitreoretinal clinic: report of 4 cases”, Can J Ophthalmol, 2009, vol. 44, pp. 444-445. [cited by applicant]
Brancato et al., “Iris fluorescein angiography in clinical practice”, Surv Ophthalmol, 1997, vol. 42, pp. 41-70. [cited by applicant]
Brenner et al., “Quantitative Importance of Changes in Postglomerular Colloid Osmotic Pressure in Mediating Glomerulotubular Balance in the Rat,” The Journal of Clinical Investigation, vol. 52, 1973, pp. 190-197. [cited by applicant]
Bugaj et al., “Pre-clinical toxicity evaluation of MB-102, a novel fluorescent tracer agent for real-time measurement of glomerular filtration rate”. Regul Toxicol Pharmacol, 2015, vol. 72, pp. 26-38. [cited by applicant]
Butner et al., “Adverse reactions in intravenous fluorescein sodium angiography”, Ann Ophthalmol, 1983, vol. 15, pp. 1084-1086. [cited by applicant]
Chahal et al., “Metabolism of fluorescein after intravenous administration”, Invest Ophthalmol Vis Sci, 1985, vol. 26, pp. 764-768. [cited by applicant]
Chinen et al., “Fluorescence-Enhanced Europium-Diethylenetriaminepentaacetic (DTPA)-Monoamide Complexes for the Assessment of Renal Function,” J. Med. Chem., vol. 51, 2008, pp. 957-962. [cited by applicant]
Davidson et al., “Anaphylaxis Associated with Intravenous Sodium Fluorescein Administration in a Cat”, Prog Vet & Comp Ophthal, 1991, vol. 1, No. 2, pp. 127-128. [cited by applicant]
Dean et al., “Inulin, Diodone, Creatinine and Urea Clearances In Newborn Infants,” J. Physiol., vol. 106, 1947, pp. 431-439. [cited by applicant]
Debreczeny et al., “Transdermal Optical Renal Function Monitoring in Humans: Development, Verification, and Validation of a Prototype Device,” Journal of Biomedical Optics, vol. 23, No. 5, May 2018, pp. 057003-1-057003-… [cited by applicant]
Dorshow et al., “Initial clinical trial results of a real-time point-of-care glomerular filtration rate measurement utilizing a novel fluorescent tracer agent”, J Am Soc Nephrol, 2015, vol. 26, pp. 259A. [cited by applicant]
Dorshow et al., “Next tier in vitro and in vivo nonclinical studies further elucidating the safety and toxicity profile of MB-102, a novel fluorescent tracer agent for measurement of glomerular filtration rate”, Regul T… [cited by applicant]
Dorshow et al.. “Clinical study results of a real-time point-of-care glomerular filtration rate measurement”, J Am Soc Nephrol, 2017, vol. 28, 12 pages. [cited by applicant]
Elman et al., “Skin necrosis following fluorescein extravasation. A survey of the Macula Society”, Retina, 1987, vol. 7, pp. 89-93. [cited by applicant]
Friedman et al., “A comparison of the renal clearances of allantoin and inulin in man,” Fed. Proc., vol. 7, No. 1 Pt 1, (1948), 1 page. [cited by applicant]
Gelatt et al., “Fluorescein angiography of the normal and diseased ocular fundi of the laboratory dog”, J Am Vet Med Assoc, 1976, vol. 169, pp. 980-984. [cited by applicant]
Gómez-Ulla et al., “Severe anaphylactic reaction to orally administered fluorescein”, Am J Ophthalmol, 1991, vol. 112, No. 94, 1 page. [cited by applicant]
Grahn et al., “Retinopathy of coton detulear dogs: clinical manifestations, electroretinographic, ultrasonographic, fluorescein and indocyanine green angiographic, and optical coherence tomographic findings”, Vet Ophtha… [cited by applicant]
Gregory et al., “Studies on Hypertension; Effect of Lowering the Blood Pressures of Hypertensive Patients by High Spinal Anesthesia on the Renal Function as Measured by Inulin and Diodrast Clearances,” Arch. Intern. Med… [cited by applicant]
Ha et al., “Anaphylaxis caused by intravenous fluorescein sodium: clinical characteristics and review of literature”, Intern Emerg Med, 2014, vol. 9, No. 3, pp. 325-330. [cited by applicant]
Hochheimer et al., “Angiography With New Dyes”, Experimental Eye Research, 1978, vol. 27, pp. 1-16. [cited by applicant]
Kinsella et al., “Anaphylaxis following oral fluorescein angiography”, Am J. Ophthalmol, 1988, vol. 106, pp. 745-746. [cited by applicant]
Kobayashi et al., “Retinal vessel changes in galactose-fed dogs”, Arch Ophthalmol, 1998, vol. 116, pp. 785-789. [cited by applicant]
Kottow, M., “Anterior segment fluorescein angiography”, Baltimore: Williams and Wilkins, 1978, pp. 35-55. [cited by applicant]
Kwiterovich et al., “Frequency of adverse systemic reactions after fluorescein sodium angiography, Results of a prospective study”, Ophthalmology, 1991, vol. 98, pp. 1139-1142. [cited by applicant]
Laatikainen, L., “Adverse effects of fluorescein angiography”, Acta Ophthalmologica Scand, 2006, vol. 84, pp. 720-721. [cited by applicant]
Levin et al., “The Effect of Chronic Anemia on Renal Function as Measured by Inulin and Diodrast Clearances,” Proc. Annu. Meet. Cent. Soc. Clin. Res. U. S., vol. 20, 1947, 3 pages. [cited by applicant]
Li et al., “Fluorescein binding to normal human serum proteins demonstrated by equilibrium dialysis”, Arch Ophthalmol, 1982, vol. 100, pp. 484-487. [cited by applicant]
Lira et al., “Adverse reactions of fluorescein angiography: a prospective study”, Arq Bras Ophthalmol, 2007, vol. 70, pp. 615-618. [cited by applicant]
Nagpal et al., “Combined Fluorescein, Indocyanine angiography and Optical Coherent Tomography Using Spectralis,” Rajasthan Journal of Ophthalmology, 2011, 8 pages. [cited by applicant]
Narfstrom et al., “Assessment of structure and function over a 3-year period after gene transfer in RPE65-/-dogs”, Doc Ophthalmol, 2005, vol. 111, pp. 39-48. [cited by applicant]
Navar et al., “Distal Tubular Feedback in the Autoregulation of Single Nephron Glomerular Filtration Rate,” J. Clin. Invest., vol. 53, 1974, pp. 516-525. [cited by applicant]
Nicholson et al., “Renal Function as Affected by Experimental Unilateral Kidney Lesions : I. Nephrosis Due to Sodium Rartrate,” J. Exp. Med., vol. 68, 1938, pp. 439-456. [cited by applicant]
Novotny et al., “A method of photographing fluorescence in circulating blood in the human retina”, Circulation, 1961, vol. 24, pp. 82-86. [cited by applicant]
Pill et al., “Fluorescein-labeled Sinistrin as Marker of Glomerular Filtration Rate,” European Journal of Medicinal Chemistry, vol. 40, 2005, pp. 1056-1061. [cited by applicant]
Pinhas et al., “In vivo imaging of human retinal microvasculature using adaptive optics scanning light ophthalmoscope fluorescein angiography”, Biomed Optics Express, 2013, vol. 4, pp. 1305-1317. [cited by applicant]
Pirie et al., “Effectiveness of MB-102, a novel fluorescent tracer agent, for conducting ocular angiography in dogs”, AJVR, May 2020, vol. 81, No. 5, pp. 428-436. [cited by applicant]
Pizzirani et al., “Transpupillary diode laser retinopexy in dogs: ophthalmoscopic, fluorescein angiographic and histopathologic study”, Vet Ophthalmol, 2003, vol. 6, pp. 227-235. [cited by applicant]
Poujeol et al., “Glomerular Filtration Rate and Microsphere Distributions in Single Nephron of Rat Kidney,” Pflugers Arch., vol. 357, 1975, pp. 291-301. [cited by applicant]
Rajagopalan et al., “Hydrophilic Pyrazine Dyes as Exogenous Fluorescent Tracer Agents for Real-Time Point-of-Care Measurement of Glomerular Filtration Rate”, Journal of Medicinal Chemistry, 2011, vol. 54, No. 14, pp. 50… [cited by applicant]
Robson et al., “The Determination of the Renal Clearance of Inulin in Man,” Q. J. Exp. Physiol., vol. 35, 1949, pp. 111-134. [cited by applicant]
Rockey et al., “Eccleston JF. Binding of fluorescein and carboxyfluorescein by human serum proteins: significance of kinetic and equilibrium parameters of association in ocular fluorometric studies”, Exp Eye Res, 1983, … [cited by applicant]
Schaepdrijver et al., Fluorescein angiography of the canine retina:, Vet Comp Ophthalmol, 1996, vol. 6, pp. 111-119. [cited by applicant]
Schock-Kusch et al., “Transcutaneous measurement of glomerular filtration rate using FITC-sinistrin in rats,” Nephrol Dial Transplant, vol. 24, 2009, pp. 2997-3001. [cited by applicant]
Shannon et al., “The Renal Excretion of Inulin and Creatinine by the Anaesthetized Dog and the Pump-Lung-Kidney Preparation”, J. Physiol., vol. 98, 1940, pp. 97-108. [cited by applicant]
Stein et al., “Reactions following intravenous fluorescein sodium”, Am J Ophthalmol, 1971, vol. 72, pp. 861-868. [cited by applicant]
Yannuzzi et al., “Effective differences in the formulation of intravenous fluorescein sodium and related side effects”, Am J Ophthalmol, 1974, vol. 78, pp. 217-221. [cited by applicant]
Yannuzzi et al., “Fluorescein angiography complication survey”, Ophthalmology, 1986, vol. 3, pp. 611-617. [cited by applicant]
Yu et al., “Rapid determination of renal filtration function using an optical ratiometric imaging approach,” Am. J. Physiol. Renal. Physiol., vol. 292, 2007, pp. F1873-F1880. [cited by applicant]
International Report and Written Opinion for PCT/US2016/32167, mailed on Aug. 19, 2016, 9 pages. [cited by applicant]
International Search Report for PCT Patent Application No. PCT/US2019/013784, mailed on May 7, 2019, 6 pages. [cited by applicant]
International Preliminary Report on Patentability for PCT Patent Application No. PCT/US2019/013784, mailed on Jul. 21, 2020, 8 pages. [cited by applicant]
Supplemental European Search Report for EP Application 16793545.1, dated Nov. 27, 2018, 8 pages. [cited by applicant]